MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.biomaterials.2025.123653

Медицинская библиотека · Biomaterials · 2025

The FN1-targeted delivery of low-molecular-weight heparin to venous clots revolutionizes thrombosis treatment in CVT.

Jiang Huimin, Chen Jian, Zhou Yifan, Zhang Weiyue, Li Hui, Ma Wei, Liu Lu, Wu Yan, Wu Chuanjie, Wu Di, Ji Xunming, Zhou Chen

СтатьяПеревод в очереди

Аннотация

The systemic administration of low-molecular-weight heparin (LMWH) as the standard initial treatment for venous thromboembolism is intended to prevent thrombus growth during the acute phase and prevent thrombus recurrence during the chronic phase. However, precisely controlling the specificity and localization of LMWH presents significant challenges, which has necessitated research into targeted delivery methods. Furthermore, due to different thrombosis mechanisms, tailored pharmacologic interventions are needed, particularly for arterial and venous thrombosis. This study employs proteomics technology to identify fibronectin (FN1) as a specific and highly expressed target protein within the thrombi of patients with cerebral venous thrombosis (CVT). Nanoparticles modified with FN1-targeting peptide cysteine-arginine-glutamic acid-lysine-alanine (CREKA) and encapsulating LMWH (CREKA-LMWH NPs) are further engineered to increase the targeting precision and therapeutic efficacy in the treatment of CVT. The in vitro and in vivo findings indicate that the CREKA-LMWH NPs effectively increase the concentration of LMWH at the thrombus site, which augments the prevention and treatment of thrombus expansion and growth without exacerbating toxic side effects. This proteomics-driven precision selection strategy boosts systemic anticoagulation effectiveness by targeting therapeutic agents to the thrombus microenvironment, offering new potential for personalized treatment by tackling the complexities of thrombus composition and formation.

Для цитирования: Jiang Huimin, Chen Jian, Zhou Yifan, Zhang Weiyue, Li Hui, Ma Wei, Liu Lu, Wu Yan, Wu Chuanjie, Wu Di, Ji Xunming, Zhou Chen. The FN1-targeted delivery of low-molecular-weight heparin to venous clots revolutionizes thrombosis treatment in CVT.. Biomaterials. 2025. DOI: 10.1016/j.biomaterials.2025.123653.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.